NO20054032L - Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene. - Google Patents

Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene.

Info

Publication number
NO20054032L
NO20054032L NO20054032A NO20054032A NO20054032L NO 20054032 L NO20054032 L NO 20054032L NO 20054032 A NO20054032 A NO 20054032A NO 20054032 A NO20054032 A NO 20054032A NO 20054032 L NO20054032 L NO 20054032L
Authority
NO
Norway
Prior art keywords
substituted
unsubstituted
preparation
intermediates
processes
Prior art date
Application number
NO20054032A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054032D0 (no
Inventor
Takashi Yamamura
Hirokazu Annoura
Kenji Murata
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Publication of NO20054032D0 publication Critical patent/NO20054032D0/no
Publication of NO20054032L publication Critical patent/NO20054032L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO20054032A 2003-02-14 2005-08-30 Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene. NO20054032L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003037397 2003-02-14
PCT/JP2004/001566 WO2004072091A1 (ja) 2003-02-14 2004-02-13 糖脂質誘導体及びその製造法並びにそれらの合成中間体及びその製造法

Publications (2)

Publication Number Publication Date
NO20054032D0 NO20054032D0 (no) 2005-08-30
NO20054032L true NO20054032L (no) 2005-11-01

Family

ID=32866358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054032A NO20054032L (no) 2003-02-14 2005-08-30 Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene.

Country Status (12)

Country Link
US (2) US7732583B2 (pt)
EP (2) EP1619199B1 (pt)
JP (2) JP4742220B2 (pt)
KR (1) KR20050105215A (pt)
CN (2) CN101165047B (pt)
AU (1) AU2004210784A1 (pt)
BR (1) BRPI0407501A (pt)
CA (1) CA2515396A1 (pt)
ES (2) ES2676345T3 (pt)
HU (1) HUE037560T2 (pt)
NO (1) NO20054032L (pt)
WO (1) WO2004072091A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1784196B1 (en) * 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
CA2613350A1 (en) * 2005-07-01 2007-01-11 Japan As Represented By President Of National Center Of Neurology And Ps Ychiatry Glycolipid derivative and drug containing the same as active component
WO2008047174A1 (en) 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
AU2008219020B2 (en) * 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
CN102325875B (zh) 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
CN101775051B (zh) * 2010-01-07 2013-03-27 北京大学 一种区域选择性脱除糖o-苄基保护基的方法
US10632740B2 (en) 2010-04-23 2020-04-28 Landa Corporation Ltd. Digital printing process
US10190012B2 (en) 2012-03-05 2019-01-29 Landa Corporation Ltd. Treatment of release layer and inkjet ink formulations
US10434761B2 (en) 2012-03-05 2019-10-08 Landa Corporation Ltd. Digital printing process
CN104271687B (zh) 2012-03-05 2016-11-02 兰达公司 油墨膜构造
US9902147B2 (en) 2012-03-05 2018-02-27 Landa Corporation Ltd. Digital printing system
US9498946B2 (en) 2012-03-05 2016-11-22 Landa Corporation Ltd. Apparatus and method for control or monitoring of a printing system
US10642198B2 (en) 2012-03-05 2020-05-05 Landa Corporation Ltd. Intermediate transfer members for use with indirect printing systems and protonatable intermediate transfer members for use with indirect printing systems
EP2822776B1 (en) 2012-03-05 2018-08-01 Landa Corporation Ltd. Transfer printing method
US9643403B2 (en) 2012-03-05 2017-05-09 Landa Corporation Ltd. Printing system
EP2823006B1 (en) 2012-03-05 2020-09-30 Landa Corporation Ltd. Ink film constructions
WO2013132418A2 (en) 2012-03-05 2013-09-12 Landa Corporation Limited Digital printing process
CN109177531B (zh) 2012-03-15 2020-11-27 兰达公司 打印系统的环形柔性皮带
AU2014214770B2 (en) 2013-02-08 2018-09-06 Albert Einstein College Of Medicine Inc. Modified glycolipids and methods of making and using the same
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
GB201401173D0 (en) 2013-09-11 2014-03-12 Landa Corp Ltd Ink formulations and film constructions thereof
US9782993B2 (en) 2013-09-11 2017-10-10 Landa Corporation Ltd. Release layer treatment formulations
GB2536489B (en) 2015-03-20 2018-08-29 Landa Corporation Ltd Indirect printing system
GB2537813A (en) 2015-04-14 2016-11-02 Landa Corp Ltd Apparatus for threading an intermediate transfer member of a printing system
DE112017002714T5 (de) 2016-05-30 2019-02-28 Landa Corporation Ltd. Digitales Druckverfahren
GB201609463D0 (en) 2016-05-30 2016-07-13 Landa Labs 2012 Ltd Method of manufacturing a multi-layer article
WO2019077489A1 (en) 2017-10-19 2019-04-25 Landa Corporation Ltd. FLEXIBLE BELT WITHOUT END FOR A PRINTING SYSTEM
JP7225230B2 (ja) 2017-11-19 2023-02-20 ランダ コーポレイション リミテッド デジタル印刷システム
WO2019102297A1 (en) 2017-11-27 2019-05-31 Landa Corporation Ltd. Digital printing system
US11707943B2 (en) 2017-12-06 2023-07-25 Landa Corporation Ltd. Method and apparatus for digital printing
US11679615B2 (en) 2017-12-07 2023-06-20 Landa Corporation Ltd. Digital printing process and method
WO2020003088A1 (en) 2018-06-26 2020-01-02 Landa Corporation Ltd. An intermediate transfer member for a digital printing system
US10994528B1 (en) 2018-08-02 2021-05-04 Landa Corporation Ltd. Digital printing system with flexible intermediate transfer member
US12001902B2 (en) 2018-08-13 2024-06-04 Landa Corporation Ltd. Correcting distortions in digital printing by implanting dummy pixels in a digital image
JP7246496B2 (ja) 2018-10-08 2023-03-27 ランダ コーポレイション リミテッド 印刷システムおよび方法に関する摩擦低減手段
WO2020136517A1 (en) 2018-12-24 2020-07-02 Landa Corporation Ltd. A digital printing system
EP3946953A4 (en) 2019-03-31 2022-12-14 Landa Corporation Ltd. SYSTEMS AND METHODS FOR PREVENTING OR MINIMIZING PRINT DEFECTS IN PRINTING PROCESSES
CN114746813A (zh) 2019-11-25 2022-07-12 兰达公司 在数字印刷中使用红外辐射来干燥油墨
US11321028B2 (en) 2019-12-11 2022-05-03 Landa Corporation Ltd. Correcting registration errors in digital printing
EP4081866A4 (en) 2019-12-29 2024-01-03 Landa Corporation Ltd. PRINTING METHOD AND SYSTEM
JP7714237B2 (ja) * 2020-11-12 2025-07-29 国立研究開発法人理化学研究所 擬似糖脂質誘導体並びにその合成中間体、製造方法及び用途
EP4264377A4 (en) 2021-02-02 2024-11-13 Landa Corporation Ltd. MITIGATION OF DISTORTIONS IN PRINTED IMAGES
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
WO2025033387A1 (ja) * 2023-08-07 2025-02-13 Eaファーマ株式会社 糖脂質誘導体の製造法及びそれらの合成中間体並びにその結晶体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6072960A (ja) * 1983-09-30 1985-04-25 Sumitomo Chem Co Ltd モノアゾ化合物およびそれを用いて染色または捺染する方法
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
AU683026B2 (en) * 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
JP2002226377A (ja) * 1996-10-14 2002-08-14 Kirin Brewery Co Ltd 配糖体含有末梢血幹細胞増加剤
JP3495740B2 (ja) * 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するNKT細胞活性化剤
EP1437358B1 (en) * 2001-08-16 2006-10-18 Daiichi Asubio Pharma Co., Ltd. Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient

Also Published As

Publication number Publication date
EP1619199B1 (en) 2013-12-18
AU2004210784A1 (en) 2004-08-26
CN1768072A (zh) 2006-05-03
EP1619199A1 (en) 2006-01-25
CN101165047B (zh) 2010-10-20
NO20054032D0 (no) 2005-08-30
CN101165047A (zh) 2008-04-23
CA2515396A1 (en) 2004-08-26
BRPI0407501A (pt) 2006-02-14
US20060074235A1 (en) 2006-04-06
EP2343306A1 (en) 2011-07-13
JP5246448B2 (ja) 2013-07-24
ES2450043T3 (es) 2014-03-21
US8034908B2 (en) 2011-10-11
US7732583B2 (en) 2010-06-08
JPWO2004072091A1 (ja) 2006-06-01
JP2011063593A (ja) 2011-03-31
ES2676345T3 (es) 2018-07-18
KR20050105215A (ko) 2005-11-03
EP1619199A4 (en) 2009-12-16
JP4742220B2 (ja) 2011-08-10
HUE037560T2 (hu) 2018-09-28
US20100210828A1 (en) 2010-08-19
EP2343306B1 (en) 2018-04-04
WO2004072091B1 (ja) 2004-11-11
CN100537585C (zh) 2009-09-09
WO2004072091A1 (ja) 2004-08-26

Similar Documents

Publication Publication Date Title
NO20054032L (no) Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene.
NO20052887L (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
EP1845081A4 (en) amide
ATE302001T1 (de) Stabilisierte askorbinsäurederivate
GB0719180D0 (en) New process
NO20076006L (no) Acetylenderivater
EA200200098A1 (ru) Ароматические сложные эфиры для маркировки или мечения нефтепродуктов
NO20031701L (no) Fremgangsmåte og mellomprodukter i fremstilling av 7- substituerte antiöstrogener
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
EP1634874A4 (en) imidazolidine
CR7249A (es) Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo
NO20013643L (no) Fremgangsmåte for fremstilling av optisk aktiv alkohol
NO20082698L (no) Nye derivater, deres salter og antisoppmidler inneholdende disse
NO20082005L (no) Syntese av renininhibitorer omfattende en cyklotilfoyelsesreaksjon
MY143665A (en) Method of producing aminophenol compounds.
DK1565451T3 (da) Halogenthienoylcyclopropan-1-carboxylsyre-derivater
NO20091779L (no) Nye indolforbindelser en prosess for deres fremstilling og farmasoytiske sammensetninger som inneholder dem
NO20062083L (no) Nye fenylpyridylpiperazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
AU6594900A (en) Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof andagents
TW200619201A (en) Process for the preparation of pyrazoles
NO20055844D0 (no) Nye benzotiazin og benzotiadiazinforbindelsep fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DE69001852D1 (de) Herstellung von derivaten der glutarsaeure.
NO20045540L (no) Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem
CY1105158T1 (el) Εκδοχα πυριδοϊνδολονης που φερει υποκαταστατη στο -3 μια ετepοκυκλικη ομαδα, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
NO20062100L (no) Nye fenylpyridylpiperazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application